The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2024 | AlloSCT for AML with MDS-related features as per the ICC and WHO 2022 classifications
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, explores the updated classification of acute myeloid leukemia (AML) with myelodysplastic (MDS)-related features according to the 2022 World Health Organization (WHO) and International Consensus Classification (ICC) guidelines. The classification categorizes patients into three groups based on TP53 nature. Those with complex karyotypes show poorer outcomes after allogeneic stem cell transplantation (alloSCT), while those with gene mutations exhibit more favorable outcomes. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
